SCHEMBL7909421

SCHEMBL7909421

C=C(NCCc1ccccn1)C(C)C

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
CYP1A2 P05177 3/20 0.58
CYP2C19 P33261 1/20 0.58
HRH3 Q9Y5N1 1/20 0.57
LMNA P02545 2/20 0.56
TAAR1 Q96RJ0 1/20 0.56
ALOX15 P16050 1/20 0.56
TAS1R3 Q7RTX0 2/20 0.54
TAS1R1 Q7RTX1 2/20 0.54
TDP1 Q9NUW8 1/20 0.53
HTT P42858 1/20 0.52
ATM Q13315 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27390797 0.83 ALDH1A1 (0.57) ALDH1A1CYP1A2CYP2C19HRH3LMNA
SCHEMBL10311684 0.83 HTT (0.64) ALDH1A1CYP1A2CYP2C19HRH3LMNA
SCHEMBL11210362 0.80 HRH3 (0.61) ALDH1A1CYP1A2CYP2C19HRH3LMNA
SCHEMBL16866627 0.79 MAPK1 (0.64) ALDH1A1HRH3LMNATAAR1ALOX15
SCHEMBL19977037 0.79 HRH3 (0.56) ALDH1A1CYP1A2CYP2C19HRH3LMNA
SCHEMBL10558453 0.77 HTT (0.62) ALDH1A1CYP1A2CYP2C19HRH3LMNA
SCHEMBL48652 0.77 HRH3 (0.61) ALDH1A1CYP1A2HRH3LMNATAAR1
SCHEMBL429129 0.77 RAB9A (0.57) ALDH1A1CYP1A2HRH3LMNATAAR1
SCHEMBL278114 0.76 CYP1A2 (0.65) ALDH1A1CYP1A2CYP2C19HRH3LMNA
SCHEMBL14519891 0.76 NPC1 (0.53) ALDH1A1CYP2C19TAAR1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759532-B2 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2014-06-24 US disclosed
US-8637500-B2 Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2014-01-28 US disclosed
US-20130079325-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS ALLEN JENNIFER R (US) 2013-03-28 US disclosed
US-8329700-B2 Pyrazine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2012-12-11 US disclosed
US-8053438-B2 Pyrazine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2011-11-08 US disclosed
US-20110160182-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2011-06-30 US disclosed
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-24 US disclosed
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160182-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE10A, PDE12, PDE5A ALDH1A1 929/4885CYP1A2 513/4885CYP2C19 603/4885
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE10A, PDE12, PDE5A ALDH1A1 929/4885CYP1A2 513/4885CYP2C19 603/4885
US-20130079325-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS PDE7A, PDE9A, PDE10A ALDH1A1 640/4885CYP1A2 979/4885CYP2C19 355/4885
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE4A, PDE7A, PDE4D ALDH1A1 1600/4885CYP1A2 1374/4885CYP2C19 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.